Prelude Therapeutics Inc logo

Prelude Therapeutics Inc

NAS:PRLD (USA)   Ordinary Shares
$ 3.82 +0.115 (+3.1%) 11:08 PM EST
At Loss
P/B:
1.00
Market Cap:
$ 209.83M
Enterprise V:
$ 25.55M
Volume:
71.64K
Avg Vol (2M):
43.31K
Trade In:
Volume:
71.64K
At Loss
Avg Vol (2M):
43.31K

Business Description

Prelude Therapeutics Inc logo
Prelude Therapeutics Inc
NAICS : 541714 SIC : 2833
ISIN : US74065P1012

Share Class Description:

PRLD: Ordinary Shares
Description
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Name Current Vs Industry Vs History
Cash-To-Debt 11.45
Equity-to-Asset 0.85
Debt-to-Equity 0.08
Debt-to-EBITDA -0.13
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 46.38
9-Day RSI 47.54
14-Day RSI 47.75
6-1 Month Momentum % 0.74
12-1 Month Momentum % -19.49

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 11.64
Quick Ratio 11.64
Cash Ratio 11.44

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -7.9
Shareholder Yield % -3.52
Name Current Vs Industry Vs History
ROE % -55.88
ROA % -49.73
ROIC % -364.3
ROC (Joel Greenblatt) % -716.54
ROCE % -58.71

Financials (Next Earnings Date:2024-08-02 Est.)

PRLD's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:PRLD

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Prelude Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.88
Beta 1.34
Volatility % 127.6
14-Day RSI 47.75
14-Day ATR ($) 0.297561
20-Day SMA ($) 3.81975
12-1 Month Momentum % -19.49
52-Week Range ($) 1.66 - 5.83
Shares Outstanding (Mil) 54.93

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Prelude Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Prelude Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Prelude Therapeutics Inc Frequently Asked Questions

What is Prelude Therapeutics Inc(PRLD)'s stock price today?
The current price of PRLD is $3.82. The 52 week high of PRLD is $5.83 and 52 week low is $1.66.
When is next earnings date of Prelude Therapeutics Inc(PRLD)?
The next earnings date of Prelude Therapeutics Inc(PRLD) is 2024-08-02 Est..
Does Prelude Therapeutics Inc(PRLD) pay dividends? If so, how much?
Prelude Therapeutics Inc(PRLD) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1